ACM
MRKR icon

ADAR1 Capital Management’s Marker Therapeutics MRKR Stock Holding History

ADAR1 Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,432
Closed -$6.86K – 272
2024
Q3 		$6.86K Buy
+2,432
New +$9.62K ﹤0.01% 260

Other funds holding MRKR

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ADAR1 Capital Management's MRKR Position: Q4 2024 in Review

ADAR1 Capital Management sold out of Marker Therapeutics (MRKR) in Q4 2024, closing a stake of 2,432 shares — an estimated $6.86K sold.

ADAR1 Capital Management first reported a position in MRKR in Q3 2024 and held it in 1 quarter. The position peaked at $6.86K in Q3 2024. 33 funds tracked by Wall St. Rank hold MRKR as of Q4 2024.

  • ADAR1 Capital Management reported no remaining Marker Therapeutics position as of Q4 2024 after selling out during the quarter.
  • ADAR1 Capital Management sold 2,432 Marker Therapeutics shares in Q4 2024, an estimated $6.86K.
  • ADAR1 Capital Management first reported a position in Marker Therapeutics in Q3 2024 and held it in 1 quarter.
  • ADAR1 Capital Management's Marker Therapeutics position peaked at $6.86K in Q3 2024.
  • 33 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2024.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.